Roche: Group sales +6% (CER) YTD; Q3 +7% (CER) and +8% in CHF
- Group sales were +6% at constant exchange rates (CER), +1% in CHF to CHF 46.5 billion in the first nine months of 2026.
- Third-quarter sales grew +7% at CER and +8% in CHF (+7% in USD) as exchange rates stabilised.
- Pharmaceuticals sales were +7% at CER to CHF 36.2 billion; top five products (Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo) totalled CHF 16.8 billion, +12% at CER.
- US FDA cleared the Elecsys pTau217 blood test; the company received US approvals for Tecentriq, Gazyva and Enspryng and US Priority Reviews for fenebrutinib and Enspryng, while the EU approved Susvimo and Ocrevus paediatric use.
Financial performance
Group sales were +6% at constant exchange rates (CER) and +1% when reported in CHF, reaching CHF 46.5 billion in the first nine months of 2026. In the third quarter, sales grew +7% at CER and +8% in CHF (+7% in USD) as exchange-rate headwinds reversed.
Division highlights
The Pharmaceuticals Division delivered +7% sales growth at CER to CHF 36.2 billion, led by Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo, which together generated CHF 16.8 billion (+12% at CER). The Diagnostics Division grew +4% at CER to CHF 10.3 billion, with core lab and pathology demand offsetting the impact of China healthcare pricing reforms.
Regulatory approvals and pipeline progress
Roche reported multiple regulatory milestones: US approvals for Tecentriq (adjuvant stage‑III dMMR colon cancer), Gazyva for paediatric frequently relapsing or steroid‑dependent idiopathic nephrotic syndrome and Enspryng in thyroid eye disease; EU approvals for Susvimo (nAMD) and Ocrevus in paediatric relapsing MS; US Priority Reviews for fenebrutinib in relapsing and primary progressive MS and for Enspryng in MOGAD; EMA validation for Enspryng in MOGAD and filing acceptance for vamikibart in uveitic macular edema. The US cleared the Elecsys pTau217 single‑biomarker blood test for Alzheimer’s amyloid pathology.
Outlook and operations
Roche confirmed its 2026 outlook: mid single‑digit Group sales growth (CER), high single‑digit core EPS growth (CER) and a further dividend increase in Swiss francs. The company is expanding manufacturing and R&D capacity in Hillsboro, Boston and Basel and aims to bring up to 20 new medicines to patients by 2030.
Source: Roche